Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7351 to 7365 of 7675 results

  1. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    In development [GID-TA11109] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.    

    Technology appraisal guidance
    Published
    27 November 2013

  3. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

    Technology appraisal guidance
    Published
    23 January 2019

  4. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Technology appraisal guidance
    Published
    20 November 2019

  5. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA855)

    NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.  

    Technology appraisal guidance
    Published
    4 January 2023

  6. Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    20 January 2015

  7. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    In development [GID-TA10926] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development [GID-TA10905] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development [GID-TA11010] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    In development [GID-TA10917] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

    This guidance has been updated and replaced by NICE diagnostics guidance 58.

    Diagnostics guidance
    Published
    19 December 2018

  13. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

    Medtech innovation briefing
    Published
    8 November 2023

  15. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Evidence summary
    Published
    24 June 2019